Rubedo Life Sciences, a Mountain View biotech, presented early data at the Aging Research and Drug Discovery meeting in Boston showing its experimental topical cream reduced the biological age of skin by about two years on average in a four-week trial of 11 people with atopic dermatitis. The analysis, performed independently by Mitra Bio using an epigenetic aging clock, found one participant saw a reduction of more than 11 years. The company also reported a 10 percent increase in a collagen linked to skin elasticity and a drop in inflammation-related markers.
The treatment works by targeting GPX4, a protein that helps senescent cells survive. By temporarily disabling it, the drug makes these "zombie" cells more susceptible to ferroptosis, a regulated form of cell death, while sparing stressed but healthy cells. In a separate 18-person trial for actinic keratosis, a sun-damage condition, the cream reduced total lesions by 46 percent after a month. Rubedo is also studying the drug for psoriasis, sun-damaged skin, and hereditary hair loss, and is developing a lower-potency over-the-counter version that could compete with retinol, as well as an oral formulation for metabolic conditions.
Outside experts welcomed the work but urged caution. Eric Verdin of the Buck Institute said he would be "circumspect" about what aging clocks really measure, noting the proliferation of such tools. Anthony Rossi, a dermatologist at Memorial Sloan Kettering, pointed out that some senescent cells are beneficial and that the science is still very early, especially for healthy skin. Both agreed that the ultimate test will be whether the skin actually looks and feels younger, not just what a biological clock says. As Rossi put it, the best anti-aging routine remains sleep, diet, and exercise. For now, the results are promising but far from proof of a commercial anti-aging breakthrough.```json {